We came across a bullish thesis on Kenvue Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on KVUE. Kenvue Inc.'s share was trading at $18.66 as of February 19th. KVUE’s trailing and forward P/E were 24.93 and 17.01, respectively according to Yahoo Finance.
[caption id="attachment_364467" align="aligncenter" width="750"]Kenvue, the newly independent consumer health company spun out from Johnson & Johnson, operates a portfolio of category-leading brands such as Tylenol, Neutrogena, and...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.